First things first about SAP and Bayer:
- According to SAP at the turning point
- Bayer is looking for a successor to expiring blockbuster drugs
With the publication of the latest quarterly figures, SAP has warned its shareholders and stated that operating profit could “stagnate or be slightly lower” than previously assumed in the next two years. Specifically, SAP is now expecting a currency-adjusted operating profit of between 8.1 and 8 for 2020 .5 billion euros, compared to 8.2 billion euros in the previous year, up to 8.7 billion euros had previously been promised.
In terms of sales, the Walldorf-based company is assuming 27.2 to 27.8 billion euros instead of the previously forecast 27.8 to 28.5 billion. In 2019 as a whole, it was 27.6 billion euros. Due to the corona pollution, the medium-term targets set for 2023 will also be postponed by one to two years.
In the third quarter of 2020, currency-adjusted sales remained stable at EUR 6.54 billion. Operating profit rose by 4 percent after adjusting for currency effects to just under EUR 2.1 billion. The bottom line is an increase in profits of 31 percent to 1.65 billion euros. This was primarily due to a valuation effect at the subsidiary Sapphire Ventures, which invests mainly money in start-ups.
The company is at “a turning point” due to the reaction of its customers to the corona pandemic, said CEO Christian Klein according to the press release. It is now a matter of aligning SAP more towards the cloud and making corresponding investments. CFO Luka Mucic said: ” Our accelerated move to the cloud will ensure we continue on our path as a cloud growth company while remaining focused on cost savings. ”
Products on SAP
The German agricultural and pharmaceutical company Bayer wants to expand its position in the gene therapy business and has therefore announced that it will be joining the US biotech company Asklepios BioPharmaceutical (AskBio). With the billion dollar deal, Bayer is also taking another step to strengthen its pharmaceutical pipeline. This is necessary because the patents of his blockbuster hits – the anticoagulant Xarelto and the eye remedy Eylea – expire in the middle of the decade. Then there is a risk of considerable sales losses due to competing products.
Bayer will initially pay two billion dollars for AskBio, which was founded in 2001 and specializes in gene therapies based on adeno-associated viruses. In addition, additional success-based milestone payments of up to two billion dollars have been agreed. “This acquisition will significantly advance the development of our cell and gene therapy business,” said Bayer CEO Werner Baumann.
AskBio has therapies for the metabolic disease Pompe disease, Parkinson’s disease and heart failure in early clinical development. “With the acquisition, our still young cell and gene therapy business is making a big leap,” said Bayer Pharmaceuticals Director Stefan Oelrich. He sees AskBio as a complement to the stem cell specialist BlueRock Therapeutics, which was acquired in 2019. It focuses on neurological and cardiological diseases, among other things.
Products on Bayer
When purchasing certificates and leverage products, investors should familiarize themselves with how they work and understand the opportunities and risks. Investors should be particularly aware of the increased risks associated with leverage products. In addition, it is essential to pay attention to the creditworthiness and thus to the risk of default of the issuer. You can obtain further important and useful information about our products by calling the toll-free number 0800 4000 910 or on our website www.hsbc-zertifikate.de.
Click here for the HSBC homepage
Are you interested in a daily delivery of our newsletter?
Subscribe for free
This document was produced by HSBC Trinkaus & Burkhardt AG (“HSBC”). It is for informational purposes only and may not be passed on to third parties without the express written consent of HSBC. The document is a marketing tool. The legal requirements for the impartiality of financial analyzes are not complied with. There is no prohibition on trading the financial products discussed before this presentation is published (“front running”). The document is also not a substitute for expert investment advice tailored to individual requirements. A subscription offer is also not yet associated with this. The document is only aimed at people who have their permanent residence / seat in Germany or Austria. It is not intended for recipients in other jurisdictions, and especially not for US citizens. Any information given on historical performance (including simulations) and forecasts of future performance of the financial products / financial indices presented are not a reliable indicator of future performance. If the discussed financial products are listed in a currency other than EUR, the return may rise or fall due to currency fluctuations. The tax treatment of an investment depends on the personal circumstances of the investor and can be subject to future changes. The information given in this document is based on sources which we believe to be reliable, but which we have not subjected to impartial testing. We do not guarantee and accept no liability for the correctness and completeness of the information contained herein.
The basic prospectuses as well as the final terms and the basic information sheets are available here. By entering the respective WKN in the search field or via the “Products” tab, you can access the individual product view. There, under “Downloads”, the relevant final terms and conditions for the individual products, which contain the terms and conditions of the offer, including the relevant terms and conditions, as well as the relevant basic information sheets can be called up.
The approval of the base prospectus by the BaFin is not to be understood as its approval of the securities offered. We recommend that interested parties and potential investors read the Base Prospectus and the Final Terms before making an investment decision in order to obtain as much information as possible, in particular about the potential risks and opportunities of the security.
You are about to acquire a product that is not easy and can be difficult to understand.
“DAX®”, “TecDAX®”, “MDAX®”, “VDAX-NEW®”, “SDAX®”, “DivDAX®”, “ÖkoDAX®”, “Entry Standard Index”, “X-DAX®” and “GEX®” are the intellectual property (including registered trademarks) of Deutsche Börse AG (“DBAG”), Deutsche Börse Group or their licensors and are used under license. The securities are neither promoted, advertised, distributed or supported in any other way by DBAG, Deutsche Börse Group or their licensors, research partners or data suppliers, and DBAG, Deutsche Börse Group and their licensors, research partners or data suppliers accept no warranty whatsoever Liability (from negligent as well as from other conduct) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.
EURO STOXX 50®, STOXX 50®, STOXX® 600 and its brands, STOXX® Europe 600 Oil & Gas, STOXX® Europe 600 Basic Resources, EURO STOXX 50® DVP are the intellectual property (including registered trademarks) of STOXX Ltd., Zug, Switzerland (“STOXX”), Deutsche Börse Group or its licensors and is used under license. The securities are neither promoted, advertised, distributed or supported in any other way by STOXX, Deutsche Börse Group or their licensors, research partners or data suppliers, and STOXX, Deutsche Börse Group and their licensors, research partners or data suppliers assume no warranty and exclude any guarantee Liability (from negligent as well as from other conduct) in this regard generally from and in particular with regard to any errors, omissions or disturbances of the relevant index or the data contained therein.
The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s®, S & P® and S&P 500® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and have been re-licensed by the licensee for certain purposes. Licensee’s products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P or their respective affiliates, and neither party makes any representations as to the advisability of investing in such product (s) and assumes no liability for any errors, omissions or interruptions in the S&P 500 Index.
Nasdaq® and Nasdaq-100 Index® are registered trademarks of Nasdaq, Inc. (together with its affiliated companies referred to as the “Companies”) and are licensed to HSBC Trinkaus & Burkhardt AG for use by them. The companies make no statement about the legality or the suitability of the securities. The companies do not issue, recommend, sell or advertise the securities. THE COMPANIES MAKE NO WARRANTY AND ASSUME NO LIABILITY IN CONNECTION WITH THE SECURITIES.
The “Dow Jones Industrial Average” is a product of S&P Dow Jones Indices LLC (“SPDJI”) and has been licensed for use by HSBC Trinkaus & Burkhardt AG (“Licensee”). Standard & Poor’s® and S & P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”), and DJIA®, The Dow®, Dow Jones® and Dow Jones Industrial Average are trademarks of Dow Jones Trademark Holdings LLC (“Dow Jones”). These trademarks have been licensed for use by SPDJI and have been re-licensed by the licensee for certain purposes. Licensee’s products are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P or their respective affiliates, and neither party makes any representations as to the advisability of investing in such product (s) and assumes no liability for any errors, omissions or interruptions in the Dow Jones Industrial Average.
Publisher: HSBC Trinkaus & Burkhardt AG, Königsallee 21/23, 40212 Düsseldorf